bg tsc revised

TReating Uncontrolled Seizures in Tuberous Sclerosis Complex

Are you or someone you care for diagnosed with tuberous sclerosis complex (TSC) and suffering from inadequate seizure control?

If you or your child have been diagnosed with TSC and have inadequate response to your existing regimen for seizure control, there may be a clinical study for you.

The TrustTSC study is exploring whether treatment with an investigational medication (ganaxolone) has the potential to reduce the frequency of seizures associated with TSC in children and adults.

Currently, there are a limited number of treatments approved specifically for individuals living with tuberous sclerosis complex (TSC). Anti-seizure medications that are available to treat seizures associated with TSC may not work for everyone, may stop working over time, or may have to be stopped because of side effects.

Find your nearest study site

About TSC

Tuberous sclerosis complex (TSC) is a rare genetic disorder that is most likely not inherited, but can be passed on from parents to their children. With more than 50,000 people in the U.S. and approximately one million people worldwide living with TSC, the disorder may affect each person differently, with signs and symptoms ranging from very mild to severe. Because TSC affects everyone differently, there is no way to predict where and how the disorder will manifest.

TSC can affect different organs in the body causing tumors to develop in the brain, skin, kidney, heart, eyes, and lungs. Seizures are the most common neurological symptom of TSC and not all individuals with TSC have the same types of seizures—so one medication may not work for all. Gaining seizure control is one of the most critical priorities for any individual with TSC-associated seizures and all efforts should be made to reduce the total number of daily seizures.

Approximately 85% of TSC patients have epilepsy and approximately 2/3 of those patients are not adequately controlled with existing anti-seizure medications. Any therapy that reduces the frequency, duration or severity of seizures may positively impact quality of life for those individuals and their families.

Find your nearest study site

little girl with tsc
young athlete

What is the TrustTSC Study?

The TrustTSC study is exploring whether treatment with investigational ganaxolone can reduce the frequency of seizures associated with TSC in children and adults. 

Ganaxolone is a neuroactive steroid that binds to GABAA receptors in the brain and is thought to help normalize over-excited neurons and provide a stabilizing effect. The purpose of the TrustTSC study is to determine whether ganaxolone could be effective as an adjunctive therapy to treat seizures in children and adults living with TSC.

The TrustTSC study is a global Phase 3 randomized, double-blind, placebo-controlled study of ganaxolone treatment in children and adults with TSC. The study consists of a 4-week baseline period defined as the first 28 days following screening (to collect seizure data), followed by a 16-week double-blind treatment phase, followed by either a 2-week down titration period or a 4-week crossover period for qualifying individuals who choose to enter the long term open-label phase.

At the screening visit to determine eligibility per inclusion/exclusion criteria, you will be asked about your seizure history, including seizure types, frequency, and seizure free days. After meeting the eligibility criteria and completing the 4-week baseline period, participants will be randomly assigned to receive either ganaxolone or placebo. Neither you, nor the study staff will know which study medication you are receiving. Participants must remain on the anti-seizure medications they are currently taking.

Find your nearest study site

Do I Qualify?

Children and adults must meet the following
criteria to be eligible for the study:

icon seizure control

Clinical or mutational TSC diagnosis (TSC1 or TSC2 mutation confirmed by your doctor)

icon ages

1-65 years old

icon seizure control

Inadequate seizure control

icon aeds

Treated with at least two prior antiseizure medications

icon studies

Not currently enrolled in any other clinical studies

The study doctor will require a pre-screening for potential participants and will ask questions about medical history and seizures to determine eligibility. You will be asked to keep track of you / your child’s seizures (including the type and number of seizures every day, and the days when you / your child doesn’t have any seizures) for four weeks.

If you require financial assistance to get to a required study visit, the sponsor will provide travel concierge services or reimbursement of reasonable travel expenses for the patient and caregiver.

Participation in the TrustTSC study is completely voluntary. Ask your doctor if being in this study is right for you or your child.

Find your nearest study site

Clinical Research

Clinical research studies evaluate investigational medications to determine if they are safe and effective for patients before they are made available to the public. Studies are carefully designed and monitored by health professionals, with participant safety as a priority.

Before enrolling in clinical research studies, participants review and sign an informed consent document, stating that the study details have been explained to them and their questions have been answered. This document is not a contract; participation in a clinical research study is completely voluntary and study participants can leave the study for any reason at any time.

shutterstock 1939051948

Frequently Asked Questions

Can participants take other antiseizure medications (ASMs) and participate in this study?

Yes. To be eligible, participants must have inadequate seizure control and been treated with at least two prior ASMs (although there are exceptions for younger participants). The TrustTSC study will allow enrollment of participants taking a full range of concomitant medications, including *EPIDIOLEX®/ EPIDYOLEX.


Is there help for transportation costs?

If you require financial assistance to get to a required study visit, the sponsor will provide travel concierge services or reimbursement of reasonable travel expenses for the participant and caregiver.

Can participants be seen by their regular physician?

For this clinical study, participants will be seen by the physician that is conducting the study. However, participants should also continue to see their regular physician, who should be notified of your treatment and condition throughout the study.

Am I guaranteed to get ganaxolone in this study?

The selection of who receives ganaxolone or placebo in the study treatment period is completely random with a 50% chance of receiving ganaxolone. During the treatment period, the study medication is blinded (unknown) to the study physician and staff, sponsor, participants, and caregivers. Following the 16-week double-blind treatment period, all completing participants have the choice to receive ganaxolone during the open-label phase of the study. During the open-label phase, all participants will receive ganaxolone.

Who can join this study?

Individuals from the ages of 1 to 65 who have a clinical or mutational diagnosis of TSC with inadequate seizure control and who have been treated with at least two prior ASMs may be eligible for the study. In addition, participants cannot be enrolled in another study with an investigational product in which they received treatment within 30 days prior to participating in TrustTSC.

See or EudraCT for details or ask your doctor if being in this study is right for you or your child.

What do I have to do to be considered for the study?

Prior to enrolling in the study, participants may need to go through a pre-screening process where the study doctor will ask questions about medical history and seizure history to see if you are a good candidate for the study. You will be asked to keep track of you/ your child’s seizures (including the type and number of seizures every day, and the days when you/ your child doesn’t have any seizures) for four weeks.

What study treatment options are provided?

Participants will be randomized into the clinical study to receive either ganaxolone or a placebo (non-active substance), in addition to their standard anti-seizure medication. The drug will be administered three times a day as a drinkable liquid, and it must be taken with food. All other medications must remain at a stable dosage while in the clinical study unless adjustments are deemed medically necessary by a physician.

Are there side effects?

All medicines can have side-effects. Ganaxolone has been generally well-tolerated in clinical studies to date. Over 1,900 people ranging from 4 months to 88 years of age have taken ganaxolone, some for as long as four years. Common side effects include sleepiness, dizziness, and fatigue.

An important aim of the TrustTSC study is to make sure that the health benefits of ganaxolone outweigh any risk or inconvenience from side effects. Before entering the study, participants will receive more detailed information on which side effects of ganaxolone treatment are already known from previous studies, and you are encouraged to talk about potential side effects with your study doctor.

Throughout the studies, your health and wellbeing will be closely monitored. If you have any specific concerns or think you might be experiencing a side-effect, you can talk to the study team at any time.

Will this help me/ my child?

Previous studies have indicated that ganaxolone may have the ability to reduce seizures associated with TSC. This study intends to find out if ganaxolone is more effective in reducing seizures compared to placebo and whether there are other benefits associated with ganaxolone treatment in TSC patients. Marinus cannot promise any benefits to participants in this research study.

Half of the participants in the study will be in the control group that receives the placebo and will not receive investigational ganaxolone. Ask your doctor if being in this study is right for you.

What is a clinical study?

Clinical studies are research studies used to help advance the understanding of a disease and find better ways to treat diseases, such as genetic epilepsies. Researchers use clinical studies to learn whether a potential drug is safe and effective.

Study Locations

Study locations are listed on and below

Map | Table

Ann & Robert H. Lurie Children’s Hospital of Chicago

Status: Coming Soon

225 E. Chicago AveChicago, IL 60611 United States

Arkansas Children’s Hospital

Status: Active

1 Children’s WayLittle Rock, AR 72202 United States

Arnold Palmer Hospital

Status: Coming Soon

100 W Gore St., 6 floorOrlando, FL 32806 United States

North Carolina
Atrium Healthcare TSC Clinic at Levine Children’s Hospital

Status: Active

100 Medical Park Drive, Suite 310 EConcord, NC 28025 United States

Boston Children’s Hospital, Harvard Medical School

Status: Coming Soon

300 Longwood AvenueBoston, MA 02115 United States

Child Neurology Consultants of Austin (CNCA)

Status: Active

5301 Davis Lane, Suite 200aAustin, TX 78749 United States

Cincinnati Children’s Hospital Medical Center

Status: Coming Soon

3333 Burnet Avenue, Neurology ML #2015 Cinncinati , OH 45229 United States

Comprehensive Neurology Clinic

Status: Active

10967 Lake Underhill Road, Suite 148 Orlando, FL 32825 United States

North Carolina
Duke University Medical Center

Status: Coming Soon

2301 Erwin RoadDurham, NC 27712 United States

New Jersey
Institute of Neurology and Neurosurgery at St. Barnabas

Status: Active

200 South Orange Ave, Suite 165Livingston, NJ 07039 United States

Le Bonheur Children’s Hospital

Status: Coming Soon

50 N DunlapMemphis, TN 38103 United States

Mayo Clinic

Status: Coming Soon

200 First Street SW Colonial B-17Rochester , MN 55905 United States

South Carolina
Medical Univ. of SC (MUSC)

Status: Active

125 Doughty Street, Suite 550ECharleston, SC 29425 United States

Mid Atlantic Epilepsy & Sleep Centre

Status: Active

6410 Rockledge Drive, Suite 610 Bethesda, MD 20817 United States

Nemours Children’s Hospital of Delaware (TSC Clinic at Nemours/duPont Hospital for Children)

Status: Coming Soon

1600 Rockland RdWilmington, DE 19803 United States

Nicklaus Children’s Hospital

Status: Coming Soon

3200 SW 60 Court #302Miami, FL 33155 United States

NW FL Clinical Research Group, LLC

Status: Active

400 Gulf Breeze ParkwayGulf Breeze, FL 32561 United States

New York
NYU Comprehensive Epilepsy Center

Status: Coming Soon

240 East 38th streetNew York, NY 10016 United States

Phoenix Children’s Hospital

Status: Coming Soon

1919 East Thomas Road, Ambulatory Building Phoenix, AZ 85016 United States

The Children’s Hospital of Philadelphia (CHOP)

Status: Coming Soon

3401 Civic Center BlvdPhiladelphia, PA 19104-4318 United States

TSC Clinic at Children’s Hospital of Michigan

Status: Coming Soon

3901 Beaubien Street Detroit , MI 48201 United States

TSC Clinic at Children’s Mercy Hosptial

Status: Coming Soon

2401 Gillham RoadKansas City, MO 64108 United States

New Jersey
TSC Clinic at Northeast Regional Epilepsy Group

Status: Coming Soon

20 Prospect Ave., Suite 800 Hackensack, NJ 07601 United States

UCLA Mattel Children’s Hospital Los Angeles Tuberous Sclerosis Clinic

Status: Coming Soon

10833 Le Conte Ave.Los Angeles, CA 90095 United States

University of Colorado Denver

Status: Coming Soon

13123 East 16th AvenueAurora, CO 80045 United States

University of Florida Gainesville

Status: Coming Soon

1505 SW Archer Road 1st FloorGainesville, FL 32608 United States

University of Missouri Child Health

Status: Coming Soon

400 N Keene St., Suite 117C Columbia , MO 65201 United States

North Carolina
University of North Carolina at Chapel Hill

Status: Coming Soon

170 Manning DrChapel Hill, NC 27599 United States

New York
University of Rochester

Status: Coming Soon

518 Hylan Building, Box 270140Rochester, NY 14642 United States

University of Texas McGovern Medical School

Status: Active

6410 Fannin, Suite 1535 Houston, TX 77030 United States

University of Utah Health Care-Pediatric Neurology

Status: Coming Soon

81 N Mario Capecchi DriveSalt Lake City, UT 84113 United States

Yale University School of Medicine

Status: Coming Soon

333 Cedar StreetNew Haven, CT 05610 United States